Search

Your search keyword '"Cerchione C"' showing total 242 results
Start Over Author "Cerchione C"
242 results on '"Cerchione C"'

2. KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

Author

Palmieri, Salvatore, Rocco, S., Vitagliano, O., Catalano, L., Cerchione, C., Vincelli, I. D., Scopelliti, A., Gentile, M., Farina, G., Barone, M., Gagliardi, A., Esposito, D., Arcamone, M., Amico, V., Fontana, R., Sementa, A., Sica, A., Svanera, G., Pane, F., and Ferrara, F.

Published
2020
Full Text
View/download PDF

3. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

Author

Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, Martinelli, G, Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G, Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, Martinelli, G, Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, and Martinelli G

Abstract

Background: Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets of patients is lacking, especially in relapsed or refractory leukemia. Methods: AVALON is a multicentric cohort study that was conducted in Italy on patients with AML who received venetoclax-based therapies from 2015 to 2020. The study was approved by the ethics committee of the participating institution and was conducted in accordance with the Declaration of Helsinki. The effectiveness and toxicity of venetoclax + HMA in 190 (43 newly diagnosed, 68 refractory, and 79 relapsed) patients with AML are reported here. Results: In the newly diagnosed AML, the overall response rate and survival confirmed the brilliant results demonstrated in VIALE-A. In the relapsed or refractory AML, the combination demonstrated a surprisingly complete remission rate (44.1% in refractory and 39.7% in relapsed evaluable patients) and conferred to treated patients a good expectation of survival. Toxicities were overall manageable, and most incidents occurred in the first 60 days of therapy. Infections were confirmed as the most common nonhematologic adverse event. Conclusions: Real-life data show that the combination of venetoclax and HMA offers an expectation of remission and long-term survival to elderly, newly diagnosed patients, and to relapsed or chemoresistant AML, increasing the chance of cure through a different mechanism of action. The venetoclax + HMA combination is expected to constitute the base for triplet combinations and integration of target therapies. Our data contribute to ameliorate the understanding of venetoclax + HMA effectiveness and toxicities in real life.

Published
2023

7. P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA

Author

Dohner, H., primary, Montesinos, P., additional, Vives Polo, S., additional, Zarzycka, E., additional, Wang, J., additional, Bertani, G., additional, Heuser, M., additional, Calado, R., additional, Schuh, A., additional, Yeh, S.-P., additional, de la Fuente, A., additional, Cerchione, C., additional, Daigle, S., additional, Hui, J., additional, Pandya, S., additional, Gianolio, D., additional, Recher, C., additional, and de Botton, S., additional

Published
2022
Full Text
View/download PDF

11. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS

Author

Bruzzese, A., primary, Derudas, D., additional, Galli, M., additional, Martino, E. A., additional, Rocco, S., additional, Conticello, C., additional, Califano, C., additional, Giuliani, N., additional, Mangicavalli, S., additional, Farina, G., additional, Lombardo, A., additional, Brunori, M., additional, Rossi, E., additional, Antonioli, E., additional, Ria, R., additional, Zambello, R., additional, Di Renzo, N., additional, Mele, G., additional, Marcacci, G., additional, Pietrantuono, G., additional, Palumbo, G., additional, Cascavilla, N., additional, Cerchione, C., additional, Belotti, A., additional, Criscuolo, C., additional, Uccello, G., additional, Curci, P., additional, Vigna, E., additional, Mendicino, F., additional, Iaccino, E., additional, Mimmi, S., additional, Botta, C., additional, Vincelli, D., additional, Sgherza, N., additional, Bonalumi, A., additional, Cupelli, L., additional, Stocchi, R., additional, Martino, M., additional, Ballanti, S., additional, Gangemi, D., additional, Gagliardi, A., additional, Gamberi, B., additional, Pompa, A., additional, Tripepi, G., additional, Frigeri, F., additional, Consoli, U., additional, Bringhen, S., additional, Zamagni, E., additional, Patriarca, F., additional, De Stefano, V., additional, Di Raimondo, F., additional, Palmieri, S., additional, Petrucci, M. T., additional, Offidani, M., additional, Musto, P., additional, Boccadoro, M., additional, Cavo, M., additional, Neri, A., additional, Morabito, F., additional, and Gentile, M., additional

Published
2022
Full Text
View/download PDF

13. Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling

Author

Orgueira, AM, Raindo, AP, Lopez, MC, Arias, JAD, Perez, MSG, Rodriguez, BA, Vence, NA, Perez, LB, Ferro, RF, Ferreiro, MA, Blanco, AA, Trabazo, EF, Cerchione C, Martinnelli G, Fernandez, PM, Encinas, MMP, and Lopez, JLB

Subjects
machine learning, gene expression, cancer, prognosis, acute myeloid leukemia, survival
Abstract

Acute Myeloid Leukemia (AML) is a heterogeneous neoplasm characterized by cytogenetic and molecular alterations that drive patient prognosis. Currently established risk stratification guidelines show a moderate predictive accuracy, and newer tools that integrate multiple molecular variables have proven to provide better results. In this report, we aimed to create a new machine learning model of AML survival using gene expression data. We used gene expression data from two publicly available cohorts in order to create and validate a random forest predictor of survival, which we named ST-123. The most important variables in the model were age and the expression of KDM5B and LAPTM4B, two genes previously associated with the biology and prognostication of myeloid neoplasms. This classifier achieved high concordance indexes in the training and validation sets (0.7228 and 0.6988, respectively), and predictions were particularly accurate in patients at the highest risk of death. Additionally, ST-123 provided significant prognostic improvements in patients with high-risk mutations. Our results indicate that survival of patients with AML can be predicted to a great extent by applying machine learning tools to transcriptomic data, and that such predictions are particularly precise among patients with high-risk mutations.

Published
2021

14. Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia

Author

Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Antelo Rodríguez B, Díaz Arias JÁ, Ferreiro Ferro R, Alonso Vence N, Bendaña López Á, Abuín Blanco A, Bao Pérez L, Melero Valentín P, González Pérez MS, Cerchione C, Martinelli G, Montesinos Fernández P, Pérez Encinas MM, and Bello López JL

Subjects
fluids and secretions, hemic and lymphatic diseases, embryonic structures, hemic and immune systems
Abstract

FLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously, a variable proportion of wild-type FLT3 patients also responded to these drugs.

Published
2021

15. Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Author

Cerchione, C., Locatelli, Franco, Martinelli, G., Locatelli F. (ORCID:0000-0002-7976-3654), Cerchione, C., Locatelli, Franco, Martinelli, G., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Acute leukemia is the most common cancer in childhood; in particular, acute lymphoblastic leukemia (ALL) represents roughly up to 80% of all cases of acute leukemias in children. Survival of children with ALL has dramatically improved over the last few decades, and is now over 90% (versus 40% of adult patients) in developed countries, except for in infants (i.e., children < 1 year), where no significant improvement was registered. Philadelphia positive ALL (Ph+ALL) accounts for around 3% of cases of childhood ALL, its incidence increasing with patient’s age. Before the era of tyrosine-kinase inhibitors (TKIs), pediatric Ph+ALL showed a worse prognosis in comparison to other forms of ALL, and was managed with intensive chemotherapy, followed, whenever possible, by allogenic hematopoietic stem cell transplantation (HSCT) in first morphological complete remission. TKIs have revolutionized the current clinical approach, which involves combinations of imatinib plus standard chemotherapy that can abrogate the negative prognostic impact conferred by the presence of BCR/ABL1 rearrangement, resulting in the probability of event-free survival (EFS) being significantly better than that recorded in the pre-TKI era. Long-term follow-up confirms these data, questioning the role of a real advantage offered by HSCT over intensive chemotherapy plus TKI in all Ph+ALL pediatric patients. Imatinib was the first generation TKI and the prototype of targeted therapy, but over the years second- (dasatinib, nilotinib, bosutinib) and third-generation (ponatinib) TKIs showed a capacity to overcome resistance to imatinib in Ph+ hematological neoplasms. Given the effectiveness of the first-in-class TKI, imatinib, also the second-generation TKI dasatinib was incorporated in the treatment regimens of Ph+ALL. In this manuscript, we will discuss the role of this drug in pediatric Ph+ALL, analyzing the available data published to date.

Published
2021

16. OUTCOMES OF RELAPSED OR REFRACTORY AND NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA AFTER HYPOMETHYLATING AGENT AND VENETOCLAX. THE ITALIAN REAL-LIFE EXPERIENCE BEFORE PUBLIC HEALTH REIMBURSEMENT (AVALON STUDY)

Author

Todisco, E, Papayannidis, C, Fracchiolla, N, Cerchione, C, Marconi, G, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Cignetti, A, Lussana, F, Mattei, D, Ciceri, F, Facchini, L, Selleri, C, Fumagalli, M, Audisio, E, Griguolo, D, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Vincenzo, F, Volpi, R, Sciume, M, Tarella, C, Rossi, G, Martinelli, G, Todisco, E, Papayannidis, C, Fracchiolla, N, Cerchione, C, Marconi, G, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Cignetti, A, Lussana, F, Mattei, D, Ciceri, F, Facchini, L, Selleri, C, Fumagalli, M, Audisio, E, Griguolo, D, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Vincenzo, F, Volpi, R, Sciume, M, Tarella, C, Rossi, G, and Martinelli, G

Published
2021

17. PCN216 An Innovative Organization MODEL to Face Risks Reduction Challenges in an Italian Cancer Center during the COVID-19 Pandemic: A Risk Reduction Estimation Study

Author

Gentili, N., primary, Roncadori, A., additional, Massa, I., additional, Florescu, C., additional, Bertoni, L., additional, Galardi, F., additional, Bucchi, L., additional, Grossi, V., additional, Vespignani, R., additional, Jani, A., additional, Cerchione, C., additional, Falcini, F., additional, and Altini, M., additional

Published
2020
Full Text
View/download PDF

26. PS1020 SNP ARRAY REVEALS A NEW DELETION OF JAK2 IN AML PATIENTS

Author

Cerchione, C., primary, Guadagnuolo, V., additional, Papayannidis, C., additional, Fontana, M.C., additional, Padella, A., additional, Iacobucci, I., additional, Simonetti, G., additional, Marconi, G., additional, Paolini, S., additional, Abbenante, M., additional, Parisi, S., additional, Volpato, F., additional, Ottaviani, E., additional, Delledonne, M., additional, Biasco, G., additional, and Martinelli, G., additional

Published
2019
Full Text
View/download PDF

28. PS997 A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1

Author

Cerchione, C., primary, Guadagnuolo, V., additional, Papayannidis, C., additional, Iacobucci, I., additional, Padella, A., additional, Simonetti, G., additional, Paolini, S., additional, Abbenante, M., additional, Parisi, S., additional, Volpato, F., additional, Fontana, M.C., additional, Ottaviani, E., additional, Testoni, N., additional, Baldazzi, C., additional, Delledonne, M., additional, Filì, C., additional, Malagola, M., additional, Cattina, F., additional, Bernardi, S., additional, Russo, D., additional, and Martinelli, G., additional

Published
2019
Full Text
View/download PDF

30. PF197 A NEW CLASSIFICATION OF ACUTE MYELOID LEUKEMIA BASED ON INTEGRATED GENOMICS AND METABOLOMICS

Author

Simonetti, G., primary, Padella, A., additional, Mengucci, C., additional, Fonzi, E., additional, Picone, G., additional, Pazzaglia, M., additional, Perricone, M., additional, Fontana, M., additional, Bruno, S., additional, Bochicchio, M.T., additional, Franchini, E., additional, Nanni, J., additional, Marconi, G., additional, do Valle, I.F., additional, De Tommaso, R., additional, Ferrari, A., additional, Ghetti, M., additional, Napolitano, R., additional, Papayannidis, C., additional, Ghelli Luseran di Rorà, A., additional, Cerchione, C., additional, Ottaviani, E., additional, Castellani, G., additional, Remondini, D., additional, Capozzi, F., additional, and Martinelli, G., additional

Published
2019
Full Text
View/download PDF

46. OUTCOMES OF RELAPSED OR REFRACTORY AND NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA AFTER HYPOMETHYLATING AGENT AND VENETOCLAX. THE ITALIAN REAL-LIFE EXPERIENCE BEFORE PUBLIC HEALTH REIMBURSEMENT (AVALON STUDY)

Author

Todisco, E., CRISTINA PAPAYANNIDIS, Fracchiolla, N., Cerchione, C., Marconi, G., Petracci, E., Zingaretti, C., Vetro, C., Martelli, M. P., Zappasodi, P., Di Renzo, N., Cignetti, A., Lussana, F., Mattei, D., Ciceri, F., Facchini, L., Selleri, C., Fumagalli, M., Audisio, E., Griguolo, D., Basilico, C., Manfra, I., Borlenghi, E., Cairoli, R., Salutari, P., Gottardi, M., Molteni, A., Martini, V., Lunghi, M., Fianchi, L., Cilloni, D., Lanza, F., Abruzzese, E., Cascavilla, N., Rivellini, F., Ferrara, F., Maurillo, L., Nanni, J., Romano, A., Cardinali, V., Gigli, F., Vincenzo, F., Volpi, R., Sciume, M., Tarella, C., Rossi, G., Martinelli, G., Todisco, E, Papayannidis, C, Fracchiolla, N, Cerchione, C, Marconi, G, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Cignetti, A, Lussana, F, Mattei, D, Ciceri, F, Facchini, L, Selleri, C, Fumagalli, M, Audisio, E, Griguolo, D, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Vincenzo, F, Volpi, R, Sciume, M, Tarella, C, Rossi, G, and Martinelli, G

Subjects
Hematology

49. INTRACELLULAR AND SYSTEMIC METABOLIC PROFILING OF ACUTE MYELOID LEUKEMIA IMPROVES GENOMIC CLASSIFICATION AND SUGGESTS NOVEL THERAPEUTIC TARGETS

Author

Simonetti, G., Padella, A., Mengucci, C., Fonzi, E., Picone, G., Pazzaglia, M., Perricone, M., Fontana, M. C., Bruno, S., Bochic-Chio, M. T., Franchini, E., Nanni, J., Marconi, G., Do Valle, I. F., Tommaso, R., Ferrari, A., Ghetti, M., Napolitano, R., CRISTINA PAPAYANNIDIS, Cerchione, C., Ottaviani, E., Castellani, G., Remondini, D., Capozzi, F., and Martinelli, G.

50. HOW TO DETECT '3C-UP', A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP

Author

Ferrari, A., Vitali, S., Robustelli, V., Ghelli, A., Baldazzi, C., Righi, S., Fonzi, E., Matteis, S., Ghetti, M., Napolitano, R., Tebaldi, M., Salvi, S., CRISTINA PAPAYANNIDIS, Marconi, G., Paolini, S., Ferrari, G., Fontana, M. C., Imbrogno, E., Padella, A., Simonetti, G., Pasquini, G., Cangini, D., Giannini, B. M., Cerchione, C., Santoro, A., Hernandez-Rivas, J. M., Calistri, D., Castellani, G., Sabattini, E., Testoni, N., Remondini, D., and Martinelli, G.

Catalog

Books, media, physical & digital resources
See catalog results